Gilead Sciences (NASDAQ:GILD) Stock Rating Lowered by TheStreet

Share on StockTwits

Gilead Sciences (NASDAQ:GILD) was downgraded by equities researchers at TheStreet from a “b” rating to a “c” rating in a report issued on Thursday, TheStreetRatingsTable reports.

Other analysts have also recently issued reports about the stock. Maxim Group reaffirmed a “hold” rating on shares of Gilead Sciences in a report on Tuesday, June 2nd. BMO Capital Markets cut shares of Gilead Sciences from an “outperform” rating to a “market perform” rating and set a $79.00 price objective for the company. in a research note on Monday, April 20th. Wells Fargo & Co reduced their price objective on shares of Gilead Sciences from $87.00 to $76.00 and set an “equal weight” rating for the company in a research note on Friday. Credit Suisse Group reduced their price objective on shares of Gilead Sciences from $75.00 to $73.00 and set a “neutral” rating for the company in a research note on Friday. Finally, Raymond James cut shares of Gilead Sciences from an “outperform” rating to a “market perform” rating in a research note on Friday, May 1st. Four analysts have rated the stock with a sell rating, sixteen have given a hold rating and nine have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $79.63.

GILD stock traded down $2.80 during midday trading on Thursday, reaching $69.53. 20,558,846 shares of the company’s stock traded hands, compared to its average volume of 6,482,609. Gilead Sciences has a 52-week low of $60.89 and a 52-week high of $85.97. The stock has a market cap of $90.73 billion, a P/E ratio of -289.70, a PEG ratio of 2.43 and a beta of 0.70. The company has a current ratio of 3.04, a quick ratio of 2.92 and a debt-to-equity ratio of 1.00. The stock’s 50-day moving average is $75.47 and its 200 day moving average is $73.57.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.11 EPS for the quarter, missing the Zacks’ consensus estimate of $1.57 by ($0.46). Gilead Sciences had a negative net margin of 1.16% and a positive return on equity of 32.17%. The business had revenue of $5.14 billion for the quarter, compared to analysts’ expectations of $5.24 billion. As a group, research analysts expect that Gilead Sciences will post 6.61 EPS for the current fiscal year.

In other Gilead Sciences news, EVP Brett A. Pletcher sold 13,210 shares of the firm’s stock in a transaction dated Tuesday, May 5th. The shares were sold at an average price of $79.23, for a total transaction of $1,046,628.30. Following the transaction, the executive vice president now owns 27,204 shares of the company’s stock, valued at approximately $2,155,372.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director John Francis Cogan sold 2,416 shares of the firm’s stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $81.75, for a total transaction of $197,508.00. Following the transaction, the director now directly owns 57,276 shares in the company, valued at approximately $4,682,313. The disclosure for this sale can be found here. Insiders have sold a total of 28,079 shares of company stock valued at $2,240,630 in the last quarter. 0.13% of the stock is currently owned by company insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Guggenheim Capital LLC increased its position in Gilead Sciences by 9.3% during the 4th quarter. Guggenheim Capital LLC now owns 917,971 shares of the biopharmaceutical company’s stock valued at $59,650,000 after purchasing an additional 78,152 shares during the period. Sontag Advisory LLC lifted its stake in Gilead Sciences by 237.4% during the 1st quarter. Sontag Advisory LLC now owns 17,971 shares of the biopharmaceutical company’s stock valued at $1,344,000 after acquiring an additional 12,644 shares during the period. Country Club Trust Company n.a. acquired a new stake in Gilead Sciences during the 1st quarter valued at approximately $224,000. Commerzbank Aktiengesellschaft FI lifted its stake in Gilead Sciences by 1.3% during the 1st quarter. Commerzbank Aktiengesellschaft FI now owns 198,441 shares of the biopharmaceutical company’s stock valued at $14,835,000 after acquiring an additional 2,557 shares during the period. Finally, Busey Wealth Management lifted its stake in Gilead Sciences by 6.4% during the 2nd quarter. Busey Wealth Management now owns 3,388 shares of the biopharmaceutical company’s stock valued at $260,000 after acquiring an additional 203 shares during the period. 78.74% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

See Also: How is Preferred Stock Different from Common Stock?

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.